Cellectis entered into an agreement this week with Takara Bio Inc. for the supplying and licensing of RetroNectin, a recombinant human fibronectin fragment.
Cellectis is a biopharmaceutical company that focuses on the development of immunotherapies based on gene edited CAR-T cells (UCART).
By gaining access to Takara’s RetroNectin, Cellectis solidifies its manufacturing process while also expanding its UCART production abilities. Under the agreement, RetroNection, due to its use in cell engineering, will be applied during the production of R&D- and GMP-grade Cellectis’ UCART product applications.
Cellectis sees the agreement with Takara as a way of fortifying the manufacturing of its vast pipeline of products while also reinforcing its vital assets and capabilities revolving around cell engineering. The collaboration with Takara gives Cellectis a chance to produce universal CAR-Ts for immunotherapy patients on a worldwide scale.
The financial terms of the agreement have not been released to the public at this time.